Cancer Immunology, Immunotherapy

, Volume 66, Issue 6, pp 731–735 | Cite as

TANTIGEN: a comprehensive database of tumor T cell antigens

  • Lars Rønn Olsen
  • Songsak Tongchusak
  • Honghuang Lin
  • Ellis L. Reinherz
  • Vladimir Brusic
  • Guang Lan ZhangEmail author
Original Article


Tumor T cell antigens are both diagnostically and therapeutically valuable molecules. A large number of new peptides are examined as potential tumor epitopes each year, yet there is no infrastructure for storing and accessing the results of these experiments. We have retroactively cataloged more than 1000 tumor peptides from 368 different proteins, and implemented a web-accessible infrastructure for storing and accessing these experimental results. All peptides in TANTIGEN are labeled as one of the four categories: (1) peptides measured in vitro to bind the HLA, but not reported to elicit either in vivo or in vitro T cell response, (2) peptides found to bind the HLA and to elicit an in vitro T cell response, (3) peptides shown to elicit in vivo tumor rejection, and (4) peptides processed and naturally presented as defined by physical detection. In addition to T cell response, we also annotate peptides that are naturally processed HLA binders, e.g., peptides eluted from HLA in mass spectrometry studies. TANTIGEN provides a rich data resource for tumor-associated epitope and neoepitope discovery studies and is freely available at or (mirror).


Immunotherapy Neoepitopes Tumor Antigens T cell epitope prediction Cancer vaccine Bioinformatics 



Basic local alignment search tool


The catalogue of somatic mutations in cancer


National Center for Biotechnology Information


Open reading frame


Tumor antigens


Tumor-specific antigens



This work was supported by The Danish Council for Independent Research Grant 4184-00211B (Lars Rønn Olsen), NIH Grant UO1 AI090043 and SU2C-AACR-DT13-14 (Ellis Reinherz) and Dana-Farber Cancer Institute, Cancer Vaccine Center Funds (Guang Lan Zhang and Vladimir Brusic).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Boon T, Cerottini JC, van den Eynde B et al (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337–365. doi: 10.1146/annurev.iy.12.040194.002005 CrossRefPubMedGoogle Scholar
  2. 2.
    Olsen L, Campos B, Winther O et al (2014) Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. BMC Med Genomics 7(Suppl 3):S2. doi: 10.1186/1755-8794-7-S3-S2 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Blum JS, Wearsch PA, Cresswell P (2013) Pathways of antigen processing. Annu Rev Immunol 31:443–473. doi: 10.1146/annurev-immunol-032712-095910 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729CrossRefPubMedGoogle Scholar
  5. 5.
    Restifo NP, Dudley ME, Rosenberg S a (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281. doi: 10.1038/nri3191 CrossRefPubMedGoogle Scholar
  6. 6.
    Gill S, June CH (2015) Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263:68–89. doi: 10.1111/imr.12243 CrossRefPubMedGoogle Scholar
  7. 7.
    Srivastava PK (2015) Neoepitopes of Cancers: Looking Back, Looking Ahead. Cancer. Immunol Res 3:969–977. doi: 10.1158/2326-6066.CIR-15-0134 Google Scholar
  8. 8.
    Reinhold B, Keskin DB, Reinherz EL (2010) Molecular Detection of Targeted Major Histocompatibility Complex I-Bound Peptides Using a Probabilistic Measure and Nanospray MS(3) on a Hybrid Quadrupole-Linear Ion Trap. Anal Chem 82:9090–9099. doi: 10.1021/ac102387t CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Reinherz EL, Keskin DB, Reinhold B (2014) Forward vaccinology: CTL targeting based upon physical detection of HLA-bound peptides. Front Immunol 5:418. doi: 10.3389/fimmu.2014.00418 PubMedPubMedCentralGoogle Scholar
  10. 10.
    Castle JC, Kreiter S, Diekmann J et al (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72:1081–1091. doi: 10.1158/0008-5472.CAN-11-3722 CrossRefPubMedGoogle Scholar
  11. 11.
    Abelin JG, Keskin DB, Sarkizova S, et al. (2017) Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity 46:315–326. doi: 10.1016/j.immuni.2017.02.007 CrossRefPubMedGoogle Scholar
  12. 12.
    Lundegaard C, Lamberth K, Harndahl M et al (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11. Nucleic Acids Res 36:W509–W512. doi: 10.1093/nar/gkn202 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    van Rooij N, van Buuren MM, Philips D et al (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:e439–e442. doi: 10.1200/JCO.2012.47.7521 CrossRefPubMedGoogle Scholar
  14. 14.
    Duan F, Duitama J, Al Seesi S et al (2014) Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 211:2231–2248. doi: 10.1084/jem.20141308 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Robbins PF, Lu Y-C, El-Gamil M et al (2013) Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747–752. doi: 10.1038/nm.3161 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kreiter S, Vormehr M, van de Roemer N et al (2015) Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520:692–696. doi: 10.1038/nature14426 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Snyder A, Makarov V, Merghoub T et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199. doi: 10.1056/NEJMoa1406498 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bresciani A, Paul S, Schommer N et al (2016) T-cell recognition is shaped by epitope sequence conservation in the host proteome and microbiome. Immunology 148:34–39. doi: 10.1111/imm.12585 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307. doi: 10.1038/nri1806 CrossRefPubMedGoogle Scholar
  20. 20.
    Reinherz EL (2015) αβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy. Cancer Immunol Res 3:305–312. doi: 10.1158/2326-6066.CIR-15-0042 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P (2013) Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun Arch 13:15Google Scholar
  22. 22.
    Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207. doi: 10.1007/s00262-004-0560-6 CrossRefPubMedGoogle Scholar
  23. 23.
    Rammensee H, Bachmann J, Emmerich NP et al (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219CrossRefPubMedGoogle Scholar
  24. 24.
    Vita R, Overton J a, Greenbaum J a et al (2015) The immune epitope database (IEDB) 3.0. Nucleic Acids Res 43:D405–D412. doi: 10.1093/nar/gku938 CrossRefPubMedGoogle Scholar
  25. 25.
    Seymour E, Damle R, Sette A, Peters B (2011) Cost sensitive hierarchical document classification to triage PubMed abstracts for manual curation. BMC Bioinform 12:482. doi: 10.1186/1471-2105-12-482 CrossRefGoogle Scholar
  26. 26.
    Olsen L, Johan Kudahl U, Winther O, Brusic V (2013) Literature classification for semi-automated updating of biological knowledgebases. BMC Genom 14(Suppl 5):S14. doi: 10.1186/1471-2164-14-S5-S14 CrossRefGoogle Scholar
  27. 27.
    Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684–693CrossRefPubMedGoogle Scholar
  28. 28.
    Safran M, Dalah I, Alexander J, et al. (2010) GeneCards Version 3: the human gene integrator. Database 2010:baq020. doi: 10.1093/database/baq020 (Oxford)CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    UniProt Consortium (2015) UniProt: a hub for protein information. Nucleic Acids Res 43:D204–D212. doi: 10.1093/nar/gku989 CrossRefGoogle Scholar
  30. 30.
    Forbes SA, Beare D, Gunasekaran P et al (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805–D811. doi: 10.1093/nar/gku1075 CrossRefPubMedGoogle Scholar
  31. 31.
    Olsen LR, Campos B, Barnkob MS et al (2014) Bioinformatics for cancer immunotherapy target discovery. Cancer Immunol Immunother 63:1235–1249. doi: 10.1007/s00262-014-1627-7 CrossRefPubMedGoogle Scholar
  32. 32.
    Altschul SF, Gish W, Miller W et al (1990) Basic local alignment search tool. J Mol Biol 215:403–410. doi: 10.1006/jmbi.1990.9999 CrossRefPubMedGoogle Scholar
  33. 33.
    Katoh K, Standley DM (2013) MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780. doi: 10.1093/molbev/mst010 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Nielsen M, Lundegaard C, Blicher T et al (2007) NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2:e796. doi: 10.1371/journal.pone.0000796 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Nielsen M, Justesen S, Lund O et al (2010) NetMHCIIpan-2.0—improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 6:9. doi: 10.1186/1745-7580-6-9 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Zhang GL, Ansari HR, Bradley P et al (2011) Machine learning competition in immunology—prediction of HLA class I binding peptides. J Immunol Methods 374:1–4. doi: 10.1016/j.jim.2011.09.010 CrossRefPubMedGoogle Scholar
  37. 37.
    Trolle T, Metushi IG, Greenbaum JA et al (2015) Automated benchmarking of peptide-MHC class I binding predictions. Bioinformatics 31:2174–2181. doi: 10.1093/bioinformatics/btv123 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Zhang GL, Sun J, Chitkushev L, Brusic V (2014) Big data analytics in immunology: a knowledge-based approach. Biomed Res Int 2014:437987. doi: 10.1155/2014/437987 PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Lars Rønn Olsen
    • 1
    • 2
  • Songsak Tongchusak
    • 1
  • Honghuang Lin
    • 1
    • 3
  • Ellis L. Reinherz
    • 1
    • 4
    • 5
  • Vladimir Brusic
    • 1
    • 6
    • 7
  • Guang Lan Zhang
    • 1
    • 7
    Email author
  1. 1.Cancer Vaccine CenterDana-Farber Cancer InstituteBostonUSA
  2. 2.Department of Bio and Health InformaticsTechnical University of DenmarkLyngbyDenmark
  3. 3.Section of Computational Biomedicine, Department of MedicineBoston University School of MedicineBostonUSA
  4. 4.Department of MedicineHarvard Medical SchoolBostonUSA
  5. 5.Laboratory of ImmunobiologyDana-Farber Cancer InstituteBostonUSA
  6. 6.School of Medicine and Bioinformatics CenterNazarbayev UniversityAstanaKazakhstan
  7. 7.Department of Computer Science, Metropolitan CollegeBoston UniversityBostonUSA

Personalised recommendations